Contrasting Auxilium Pharmaceuticals (AUXL) & Mediwound (MDWD)

Auxilium Pharmaceuticals (NASDAQ: AUXL) and Mediwound (NASDAQ:MDWD) are both small-cap biopharmaceuticals companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Insider & Institutional Ownership

29.5% of Mediwound shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for Auxilium Pharmaceuticals and Mediwound, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Auxilium Pharmaceuticals 0 0 0 0 N/A
Mediwound 0 0 5 0 3.00

Mediwound has a consensus target price of $9.80, indicating a potential upside of 139.61%. Given Mediwound’s higher possible upside, analysts clearly believe Mediwound is more favorable than Auxilium Pharmaceuticals.

Volatility and Risk

Auxilium Pharmaceuticals has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, Mediwound has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500.

Earnings & Valuation

This table compares Auxilium Pharmaceuticals and Mediwound’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Auxilium Pharmaceuticals N/A N/A N/A ($3.27) -11.15
Mediwound $1.56 million 70.92 -$18.88 million ($0.98) -4.17

Auxilium Pharmaceuticals has higher earnings, but lower revenue than Mediwound. Auxilium Pharmaceuticals is trading at a lower price-to-earnings ratio than Mediwound, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Auxilium Pharmaceuticals and Mediwound’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Auxilium Pharmaceuticals -29.78% -76.75% -11.59%
Mediwound -904.26% -246.58% -39.43%

Summary

Mediwound beats Auxilium Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

About Auxilium Pharmaceuticals

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in men’s healthcare. The company’s products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.

About Mediwound

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

Receive News & Ratings for Auxilium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auxilium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply